De-risking Phase I/II trials for emerging biotech innovators
J Gordon, L Timmerman, D Schaumberg et al.
Ensuring success in AAV scale-up: key data from case studies across four serotypes
Kelly Cybulski, Kyle Burrell
Managing raw material changes in cell & gene therapy: ensuring compliance and consistency
J King-Hart, M Mendicino, K Kime et al.
Enabling scalable CAR-T therapies with next-gen animal component-free T cell media
Pedro Azevedo Da Silva Couto, Rukmini Ladi
Ensuring success in AAV scale-up: key data from case studies across four serotypes (APAC)
K Cybulski, K Burrell, A Low (Joining for Q&A)